Along with the progress of the insurance benefit procedure, "Braftovi," which lowers the BRAF, will be prescribed at general hospitals.

According to related industries, Braftovi (Encorafenib), a treatment for colorectal cancer in Ono Pharmaceutical Industry, passed the Pharmaceutical Affairs Committee (DC) of Korea University Anam Hospital, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, and Asan Medical Center. Braftovi can be used as a combination therapy with Erbitux (Cetuximab) of Merck Korea in adult patients with direct bowel cancer with previous treatment experience and confirmed BRAF V600E mutation. It is currently in the process of registering b